1
Cary L Queen, William P Schneider, Harold E Selick: Polynucleotides encoding improved humanized immunoglobulins. Protein Design Labs, Townsend and Townsend and Crew, December 2, 1997: US05693761 (692 worldwide citation)

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immuno ...


2
Charles A Parkos, Dominique A Weber: JAML specific binding agents, antibodies, and uses related thereto. Emory University, Emory Patent Group, March 28, 2017: US09605083

Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.


3
ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USES THEREOF. March 23, 2017: US20170081398-A1

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.


4
JAML Specific Binding Agents, Antibodies, and Uses Related Thereto. May 30, 2019: US20190161545-A9

Certain embodiments of the disclosure relate to targeted binding agents that specifically bind to JAM-like protein and therein inhibit epithelial damage. Although it is not intended that embodiments of the disclosure be limited by any particular mechanism, it is believed that a possible mechanism by ...